Douglas Morris Net Worth

Douglas Morris biography

Douglas P. Morris serves as Director, Secretary, Director of Investor Relations of the Company. Mr. Morris is a co-founder of Bio-Path and has served as a director of Bio-Path since 2007 and served as an officer from 2007 to June 2014. Mr. Morris also currently serves as the Director of Investor Relations and the Secretary of Bio-Path. Mr. Morris previously served as a co-founder, Managing Member, and Secretary of nCAP Holdings, LLC (nCAP), a privately held technology based company from September 2013 to January 2016. Between 1993 and 2010, Mr. Morris was an officer and director of Celtic Investment, Inc., a financial services company. Mr. Morris owned and operated Hyacinth Resources, LLC (“Hyacinth”), a business-consulting firm, from 1990 until September 2018, and is also a Managing Member of Sycamore Ventures, LLC, a privately held consulting firm. Mr. Morris has a B.A. from Brigham Young University, and attended the University of Southern California Master’s program in public administration.

What is the salary of Douglas Morris?

As the Director、 Secretary、 Director of Investor Relations of Bio-Path Inc, the total compensation of Douglas Morris at Bio-Path Inc is 52,000$. There are 2 executives at Bio-Path Inc getting paid more, with Peter Nielsen having the highest compensation of 734,734$.

How old is Douglas Morris?

Douglas Morris is 64, he's been the Director、 Secretary、 Director of Investor Relations of Bio-Path Inc since 2018. There are 3 older and 3 younger executives at Bio-Path Inc. The oldest executive at Bio-Path Holdings Inc is Peter H. Nielsen MBA, 72, who is the Co-Founder, Chairman, CEO, Pres, CFO & Treasurer.

What's Douglas Morris's mailing address?

Douglas's mailing address filed with the SEC is 2800 Wild Mare Way, Heber City, UT 84032, USA.

Insiders trading at Bio-Path Inc

Over the last 16 years, insiders at Bio-Path Inc have traded over 171,456$ worth of Bio-Path Inc stock and bought 1,226,067 units worth 451,466$ . The most active insiders traders include Capital, Llc Armistice Capi...、Thomas E Garrison、Michael J. Garrison. On average, Bio-Path Inc executives and independent directors trade stock every 423 days with the average trade being worth of 156,477$. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 18 January 2019, trading 64,457 units of BPTH stock currently worth 171,456$.

What does Bio-Path Inc do?

bio-path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary dnabilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. the company’s initial focus is in oncology. bio-path’s lead product candidate, prexigebersen, (bp1001), is in phase ii clinical trials for aml in combination with ldac in elderly de novo patients. the safety segment of the phase ii trial for prexigebersen + dasatinib in blast-phase and accelerated phase cml patients is expected to begin in 2017. bio-path’s second drug candidate, bp1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. the technology behind prexigebersen is called dnabilize™ technology. dnabilize is a liposomal antisense dna platform with two critical improvements in oligonucleotide therapeutics. the main benefits to the patient are, 1: we have never had a single patient experience thrombocytopen

Bio-Path Inc executives and stock owners

Bio-Path Inc executives and other stock owners filed with the SEC include:

• Peter Nielsen,
  Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer, Treasurer
• Peter H. Nielsen MBA,
  Co-Founder, Chairman, CEO, Pres, CFO & Treasurer
• Douglas Morris,
  Director, Secretary, Director of Investor Relations
• Douglas P. Morris,
  Co-Founder, Director of Investor Relations, Sec. & Director
• Martina Molsbergen,
  Independent Director
• Heath Cleaver,
  Independent Director
• Paul Aubert,
  Independent Director
• Victoria Lake Rac,
  Regulatory Consultant
• Dr. Jeffery Lancet M.D.,
  Consultant
• Dr. Thomas A. Walker Ph.D.,
  Consultant
• Dr. Alan MacKenzie Ph.D.,
  Consultant
• Dr. Ana Tari Ashizawa Ph.D., MBA,
  Sr. VP of Research, Devel. & Clinical Design
• Anthony Price,
  Sr. VP of Fin., Accounting & Admin.
• Amy Sing,
  Director
• Ulrich W. Mueller,
  Chief Operating Officer
• Michael J. Garrison,
  Director
• Mark P Colonnese,
  Director
• Capital, Llc Armistice Capi...,
  
• Gillian C Ivers Read,
  Director
• Thomas E Garrison,
  Director
• Aline Sherwood,
  Director